NASDAQ:NAMS NewAmsterdam Pharma Q4 2025 Earnings Report $25.38 -0.48 (-1.84%) As of 03:55 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast NewAmsterdam Pharma EPS ResultsActual EPS-$0.63Consensus EPS -$0.40Beat/MissMissed by -$0.23One Year Ago EPSN/ANewAmsterdam Pharma Revenue ResultsActual Revenue$0.19 millionExpected Revenue$0.92 millionBeat/MissMissed by -$730.00 thousandYoY Revenue GrowthN/ANewAmsterdam Pharma Announcement DetailsQuarterQ4 2025Date2/18/2026TimeBefore Market OpensConference Call DateWednesday, February 18, 2026Conference Call Time7:00AM ETUpcoming EarningsNewAmsterdam Pharma's Q3 2026 earnings is estimated for Wednesday, November 4, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 5, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (6-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(6-K)Annual report(10-K) NewAmsterdam Pharma Earnings HeadlinesNewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 3 at 4:01 PM | globenewswire.comNewAmsterdam Pharma to Participate at Upcoming Investor Conferences in SeptemberSeptember 2 at 8:00 AM | globenewswire.comBank of America grew this stake 139%Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, and Millennium by 122%. Kopernik Global made it their largest holding, owning roughly 8% of the company. It holds rights to an 88 million ounce deposit with existing roads, power, and permits that never expire. Market cap sits near $4 billion against a deposit worth hundreds of billions at current gold prices.September 4 at 1:00 AM | Behind the Markets (Ad)NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026August 26, 2026 | globenewswire.comNeedham Remains a Buy on NewAmsterdam Pharma Company (NAMS)August 23, 2026 | theglobeandmail.comNewAmsterdam Pharma Company N.V. (NAMS) Analyst/Investor Day TranscriptAugust 8, 2026 | seekingalpha.comSee More NewAmsterdam Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like NewAmsterdam Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NewAmsterdam Pharma and other key companies, straight to your email. Email Address About NewAmsterdam PharmaNewAmsterdam Pharma (NASDAQ:NAMS), Inc. is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism. The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation. These investigational compounds are designed to improve glycemic control, support weight management and reduce cardiometabolic risk factors. NewAmsterdam Pharma’s programs emphasize oral delivery formats and aim to provide differentiated safety and efficacy profiles compared with existing therapies. Headquartered in the United States, NewAmsterdam Pharma leverages a network of research collaborations with academic institutions and industry partners to accelerate its discovery and development activities. The company’s strategic alliances support advancement of its clinical candidates through regulatory milestones and position it to pursue global development and commercialization opportunities for patients with metabolic disorders. View NewAmsterdam Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Snowflake’s AI Momentum Is Forcing a Fresh Look at the StockAeroVironment’s $465 Million Army Laser Win Expands Its Counter-Drone OpportunityFB Financial's Southern Expansion and Buybacks Drive Analyst OptimismRetail Earnings Just Exposed a Bigger Divide in the U.S. Consumer EconomyAccelerant’s Take-Private Deal Raises a Bigger Question for Insurance StocksDefense Stocks Are Pulling Back as Their Navy Tailwinds Get StrongerThe Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story Upcoming Earnings Adobe (9/10/2026)Oracle (9/10/2026)FedEx (9/17/2026)Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
